Drug Profile
CTX 009
Alternative Names: ABL-001; ABL001 - ABL Bio; CTX-009; ES 104; HD-B001A; NOV1501; TR-009Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator ABL Bio
- Developer ABL Bio; Compass Therapeutics; Elpiscience Biopharmaceuticals; National OncoVenture
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Biliary cancer
- Phase II Colorectal cancer
- Phase I Solid tumours
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumors released by Compass Therapeutics
- 10 May 2023 Compass Therapeutics has patent protection for DLL4/VEGF antibody program including CTX 009 in USA and foreign jurisdictions
- 10 May 2023 Compass Therapeutics plans clinical trials for Biliary tract cancer, Colorectal cancer, and Ovarian cancer in USA (Compass Therapeutics pipeline, May 2023)